Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - PowerPoint PPT Presentation

Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q4FY15 & FY14-15

Safe Harbor Statement • Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof. Investor Presentation May 2015 2

Introduction to Wockhardt Key Business Dynamics

Wockhardt Today UK, Ireland, France, Switz. Direct Operations USA in India , USA Mexico and Europe India 8600 Associates employed in 21 countries Wockhardt Direct ROW operations operations Investor Presentation May 2015 4

Wockhardt Today UK Ireland 9 sites 12 Chicago in India Baddi Manufacturing Locations globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formulations APIs Investor Presentation May 2015 5

Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation May 2015 6

Key Business Update

Key Business Update Regulatory Update  UK MHRA lifted Statement of Non Compliance from L1 Facility and have also restored EU GMP certification of Kadaiya facility.  MGP Facility:- 483 response was found satisfactory from US FDA.  US FDA conducted inspection in L1 & Waluj facilities & observed on going improvement in company's efforts towards compliance. Research Update  Obtained QIDP status from US FDA for 2 of its drugs WCK 771 & WCK 2349 for New Drug Discovery program in Anti-infective research in FY15. Also obtained QIDP status for its third NCE product WCK 4873 during this month. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.  Filed for 267 patents during the Year taking the cumulative filings to 2268 and has been granted 82 patents during the Year taking the cumulative patents granted to 341. Investor Presentation May 2015 8

Q4FY15 Results

Sales – Growth of 4% over Q4FY14 Rs.crore Growth of 4% in Q4FY15 over Q4FY14 Investor Presentation May 2015 10

EBITDA – Growth of 11% over Q4FY14 Rs.crore Growth of 11% in Q4FY15 over Q4FY14 Investor Presentation May 2015 11

PAT – Decline of 55% over Q4FY14 Rs.crore De-growth of 55% in Q4FY15 over Q4FY14 Investor Presentation May 2015 12

FY 14-15 Results

Sales – Decline of 7% over FY 13-14 Rs.crore Decline of 7% in FY 14-15 over FY 13-14 Investor Presentation May 2015 14

EBITDA – Declines by 16% over FY 13-14 Rs.crore Declines by 16% in FY 14-15 over FY 13-14 Investor Presentation May 2015 15

PAT – Declines by 52% over FY 13-14 Rs.crore Declines by 52% in FY 14-15 over FY 13-14 Investor Presentation May 2015 16

Research – 11.5% of Sales in FY14-15 Investor Presentation May 2015 17

US Business • Declines by 21% (22% in $ terms) over Q4FY14. USA • Declines by 49% (51% in $ terms) 2,500 $364 2,000 over FY 13-14. • During the year 14 ANDA’s filed & 1,500 Rs.cr. $179 1,000 cumulative ANDA’s pending for 500 approval is 69. 2,150 1,087 - FY 13-14 FY 14-15 Investor Presentation May 2015 18

EU Operations UK Operations UK £ 141 1,500 • 8 New Approvals received in FY 14-15. 1,300 • 11 New Fillings done in FY 14-15 , 1 in Q4FY15. 1,100 £ 104 900 • Rs.cr. UK operation Grows by 36% (grows by 34% £ terms) in 700 Q4FY15. Grows by 46% (35% in £ terms) in FY 14-15. 500 • Among top 5 generic company. 300 964 1,405 100 FY 13-14 FY 14-15 Ireland 250 Ireland Operations 200 € 22 € 20 • Ireland Declines by 11% (6% in € terms) in Q4FY15. 150 Rs.cr. Decline by 10% (11% in € terms) in FY 14-15. 100 50 176 158 - FY 13-14 FY 14-15 Investor Presentation May 2015 19

India & Emerging Markets • Total Emerging Markets (Including India) Grows by 26% for Q4FY15. Grows by 19% for FY 14-15. • India Business Grows by 46% for Q4FY15 and Grows by 24% during FY 14-15. • 2 new products in Q4FY15 and 42 new India & Emerging Markets (Em) 1,800 products launched in FY 14-15 in India. 1,600 • Emerging Market operations declined by 312 1,400 Em 302 25% in Q4FY15 and grew by 3% during FY 1,200 Em 1,000 Rs.cr. 14-15. 800 1235 998 600 India India 400 200 0 FY 13-14 FY 14-15 Investor Presentation May 2015 20

For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com 21 Investor Presentation May 2015